These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32108383)

  • 1. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder.
    Baron M; Perrouin-Verbe MA; Lacombe S; Paret F; Le Normand L; Cornu JN
    Neurourol Urodyn; 2020 Mar; 39(3):1012-1019. PubMed ID: 32108383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
    Marcelissen TA; Rahnama'i MS; Snijkers A; Schurch B; De Vries P
    World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients.
    Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA
    Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review.
    Zhang Y; Ji F; Liu E; Wen JG
    Urol Int; 2021; 105(11-12):929-934. PubMed ID: 34130295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
    Jiang YH; Kuo HC
    Neurourol Urodyn; 2017 Feb; 36(2):338-343. PubMed ID: 26575613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study.
    Liao CH; Chen SF; Kuo HC
    Neurourol Urodyn; 2016 Aug; 35(6):717-23. PubMed ID: 25914349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
    Amundsen CL; Richter HE; Menefee SA; Komesu YM; Arya LA; Gregory WT; Myers DL; Zyczynski HM; Vasavada S; Nolen TL; Wallace D; Meikle SF
    JAMA; 2016 Oct; 316(13):1366-1374. PubMed ID: 27701661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review].
    Henriet B; Roumeguère T
    Rev Med Brux; 2015; 36(1):29-37. PubMed ID: 25856969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease].
    Atamian A; Sichez PC; Michel F; Bandelier Q; Fall M; Gaillet S; Azoulay JP; Lechevallier E; Karsenty G
    Prog Urol; 2021 Jun; 31(7):430-438. PubMed ID: 33579624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure.
    Karsenty G; Baverstock R; Carlson K; Diaz DC; Cruz F; Dmochowski R; Fulford S; Giannantoni A; Heesakkers J; Kaufmann A; Peyrat L; Thavaseelan J; Dasgupta P
    Int J Clin Pract; 2014 Jun; 68(6):731-42. PubMed ID: 24472109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes.
    Habashy D; Losco G; Tse V; Collins R; Chan L
    BJU Int; 2015 Oct; 116 Suppl 3():61-5. PubMed ID: 26176660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
    Peyronnet B; Castel-Lacanal E; Manunta A; Roumiguié M; Marque P; Rischmann P; Gamé X
    Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
    Timm B; Jayarajan J; Chan G; Bolton D
    Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease.
    Vurture G; Peyronnet B; Feigin A; Biagioni MC; Gilbert R; Rosenblum N; Frucht S; Di Rocco A; Nitti VW; Brucker BM
    Neurourol Urodyn; 2018 Nov; 37(8):2669-2677. PubMed ID: 29767449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery.
    Miotla P; Futyma K; Cartwright R; Bogusiewicz M; Skorupska K; Markut-Miotla E; Rechberger T
    Int Urogynecol J; 2016 Mar; 27(3):393-8. PubMed ID: 26364180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.